简短报告：伴有柔脑膜癌病的EGFR L833V/H835L双突变非小细胞肺癌对奥希替尼有反应 - Suppr

Suppr

超能文献

Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.

作者信息

Smith Jarrod T, Puri Sonam, Akerley Wallace

机构信息

Department of Internal Medicine, University of Utah, Salt Lake City, UT.

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.

出版信息

Clin Lung Cancer. 2023 Jun;24(4):360-361. doi: 10.1016/j.cllc.2023.01.010. Epub 2023 Feb 9.

DOI:10.1016/j.cllc.2023.01.010

PMID:36935243

Abstract

摘要

相似文献

Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.简短报告：伴有柔脑膜癌病的EGFR L833V/H835L双突变非小细胞肺癌对奥希替尼有反应

Clin Lung Cancer. 2023 Jun;24(4):360-361. doi: 10.1016/j.cllc.2023.01.010. Epub 2023 Feb 9.

Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.曲美替尼克服了 EGFR 突变型肺癌脑膜转移模型中 KRAS-G12V 诱导的奥希替尼耐药。

Cancer Sci. 2021 Sep;112(9):3784-3795. doi: 10.1111/cas.15035. Epub 2021 Jul 22.

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.奥希替尼治疗 EGFR 突变型非小细胞肺癌伴 EGFR 酪氨酸激酶抑制剂预处理性脑膜转移的疗效。

Target Oncol. 2018 Aug;13(4):501-507. doi: 10.1007/s11523-018-0581-2.

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.阿法替尼帮助克服 NSCLC 伴脑膜转移患者奥希替尼后继发性耐药，该患者存在获得性 EGFR L718Q 突变：一例报告。

BMC Cancer. 2019 Jul 17;19(1):702. doi: 10.1186/s12885-019-5915-7.

Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.奥希替尼在一名伴有软脑膜转移和EGFR罕见S768I突变患者中的疗效。

Lung Cancer. 2020 May;143:95-96. doi: 10.1016/j.lungcan.2020.03.016. Epub 2020 Mar 18.

Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.表皮生长因子受体（EGFR）突变的非小细胞肺癌合并软脑膜转移患者中奥希替尼治疗结果的预测指标

J Cancer Res Clin Oncol. 2023 Jan;149(1):5-14. doi: 10.1007/s00432-022-04396-1. Epub 2022 Nov 1.

Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant ( L833V / H835L ) lung adenocarcinoma patient: a case report.一线奥希替尼单药治疗复杂表皮生长因子受体突变（L833V/H835L）肺腺癌患者的完全缓解：一例报告。

Anticancer Drugs. 2023 Sep 1;34(8):939-941. doi: 10.1097/CAD.0000000000001523. Epub 2023 Apr 28.

[A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation  and Literature Review].[1例罕见的伴有EGFR L833V/H835L共突变的肺腺癌病例及文献复习]

Zhongguo Fei Ai Za Zhi. 2023 Oct 20;26(10):795-800. doi: 10.3779/j.issn.1009-3419.2023.102.36.

Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease.表皮生长因子受体突变型非小细胞肺癌伴软脑膜疾病患者的系统治疗模式和结局。

Clin Lung Cancer. 2022 Jul;23(5):446-455. doi: 10.1016/j.cllc.2022.03.013. Epub 2022 Apr 29.

Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.奥希替尼治疗1例无T790M突变的EGFR+非小细胞肺癌软脑膜转移患者的临床疗效分析

Ann Palliat Med. 2019 Nov;8(5):525-531. doi: 10.21037/apm.2019.10.13.

引用本文的文献

Rare exon 18 G719A and exon 21 L833V compound EGFR mutations show favorable response to Third-Generation TKI Furmonertinib: A case report and literature review.罕见的外显子18 G719A和外显子21 L833V复合表皮生长因子受体（EGFR）突变对第三代酪氨酸激酶抑制剂（TKI）伏美替尼显示出良好反应：一例报告及文献综述

Invest New Drugs. 2025 Apr;43(2):425-432. doi: 10.1007/s10637-025-01521-y. Epub 2025 Mar 27.

[A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation  and Literature Review].[1例罕见的伴有EGFR L833V/H835L共突变的肺腺癌病例及文献复习]

Zhongguo Fei Ai Za Zhi. 2023 Oct 20;26(10):795-800. doi: 10.3779/j.issn.1009-3419.2023.102.36.

Successful treatment of lung adenocarcinoma complicated with a rare compound mutation L833V/H835L using aumolertinib: a case report and literature review.奥莫替尼成功治疗罕见复合突变L833V/H835L的肺腺癌：病例报告及文献综述

Front Pharmacol. 2023 Aug 29;14:1257592. doi: 10.3389/fphar.2023.1257592. eCollection 2023.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验